Dear colleague,
As 2018 draws to a close and long awaited large scale clinical trial data surfaces, there is a buzz in the air surrounding all things hot in malignant and non-malignant hematology. As we look ahead to 2019 new questions arise, such as: how are researchers tackling solid tumours, how is the industry managing toxicity and what are the novel antigens that CAR-T can target?
We are therefore delighted to announce that Dr Alessandro Riva, Executive Vice President Oncology Therapeutics at Gilead will be giving a keynote address at the 4th annual CAR-T USA Congress in Boston, April 16-17, 2019.
|
